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Abstract
BACKGROUND AND STUDY AIMS: The role of endoscopic submucosal
dissection (ESD) in Barrett's neoplasia is ill-defined, although it might provide a
higher curative resection rate and better histologic assessment than endoscopic
mucosal resection (EMR). We aimed to assess efficacy, safety, and long-term
results of ESD. PATIENTS AND METHODS: A retrospective analysis was done of
75 consecutive patients with Barrett's esophagus who underwent ESD between
January 2007 and February 2014. ESD was performed for visible lesions that
were multiple, larger than 15 mm, or poorly lifting, or suspected of submucosal
infiltration. The primary end point was the rate of curative resection of carcinoma.
RESULTS: Median patient age was 68 years (interquartile range [IQR] 61 -
 76), median follow-up was 20 months (IQR 8.5 - 37.5), and median maximum
specimen diameter was 52.5 mm (IQR 43 - 71). En bloc resection rate was 90 %
(66 /73), and rates of curative resection of carcinoma and hig...
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Introduction
!
The worldwide burden of invasive esophageal
adenocarcinoma (EAC), with records of its rising
incidence and poor prognosis, has focused inter-
est on Barrett’s esophagus, a preneoplastic condi-
tion caused by gastroesophageal reflux disease
[1,2]. The Barrett esophagus–EAC progression
was first documented in the 1970s, providing tar-
gets for the screening, monitoring, and endo-
scopic management of early-stage neoplasia.
High grade dysplasia (HGD) and adenocarcinoma
limited to the mucosa are the two indications for
which endoscopic treatment is recommended [3,
4]. Based on the findings of Japanese studies per-
taining to early-stage gastric neoplasia, European
publications have suggested the existence of a
submucosal EAC subtype (pT1bsm1) associated
with a very low risk for lymph node metastasis
[5,6]. For patients who have this particular sub-
type with low risk characteristics, recent guide-
lines have advised endoscopic excision as a valid
alternative to esophagectomy [3,4].
The endoscopic management of Barrett’s neopla-
sia consists of two steps [3]: first, the excision of
endoscopically visible abnormalities for accurate
diagnosis and staging [7,8], and second, eradica-
tion of the residual Barrett esophagus segment
because of its metachronous lesion risk, which
exceeds 20% over a 2-year period [9]. Endoscopic
mucosal resection (EMR) appears to be the treat-
ment of choice for the excision procedure, with
the advantages of being safe, effective, and the
most comprehensively studied method [9–12].
In a prospective trial of EMR for mucosal cancer
in 288 patients, complete responses were
achieved in 97% and 87% of them after a median
of 3 and 61 months, respectively [9]. No death
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Background and study aims: The role of endo-
scopic submucosal dissection (ESD) in Barrett’s
neoplasia is ill-defined, although it might provide
a higher curative resection rate and better histo-
logic assessment than endoscopic mucosal resec-
tion (EMR). We aimed to assess efficacy, safety,
and long-term results of ESD.
Patients and methods: A retrospective analysis
was done of 75 consecutive patients with Bar-
rett’s esophagus who underwent ESD between
January 2007 and February 2014.ESD was per-
formed for visible lesions that were multiple, lar-
ger than 15mm, or poorly lifting, or suspected of
submucosal infiltration. The primary end point
was the rate of curative resection of carcinoma.
Results: Median patient age was 68 years (inter-
quartile range [IQR] 61–76), median follow-up
was 20 months (IQR 8.5–37.5), and median max-
imum specimen diameter was 52.5mm (IQR 43–
71). En bloc resection rate was 90% (66/73), and
rates of curative resection of carcinoma and high
grade dysplasia/carcinoma were 85% (47/55)
and 64% (42/66), respectively. G3 differentiation
and invasion to greater than pT1m2 were ob-
served in 25% (14/55) and 67% (37/55) of pa-
tients with adenocarcinoma, respectively. There
were 5 early (<48 hours) adverse events (2 de-
layed hemorrhages and 3 perforations), all treat-
ed endoscopically. No ESD-specific death occurr-
ed. Esophageal strictures developed in 60% of pa-
tients, all treated endoscopically. Additional treat-
ment (median sessions 2 [IQR 2–3]) for residual
Barrett’s esophagus were recommended to 62%
(42/68). At latest follow-up, complete remission
of neoplasia and intestinal metaplasia was found
in 92% (54/59) and 73% (43/59) of patients,
respectively.
Conclusion: ESD appears to be safe and effective,
with a high rate of curative resection of carcino-
ma. ESD should be considered for patients with
Barrett’s neoplasia at risk of incomplete resection
or poor pathologic assessment with conventional
EMR.
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related to Barrett’s neoplasia was recorded at last follow-up [9].
This procedure, however, allows only piecemeal resection and is
limited to lesions smaller than 15mm. As for the eradication of
residual Barrett’s esophagus, several ablative techniques have
been described [13–15], with radiofrequency ablation (RFA) cur-
rently considered the most effective method with the best side-
effect profile [4,16]. Nevertheless, this technique does not pro-
vide specimens for histopathologic evaluation, and the procedure
is expensive and not reimbursed by national health systems in
some countries. Stepwise radical endoscopic resection (SRER)
has also been suggested, although strictures occur in half of the
patients [17,18].
Endoscopic submucosal dissection (ESD) has recently emerged as
a potential technique to improve complete resection rates. In a
meta-analysis, ESD was shown to achieve better rates of en bloc
and curative resection and less local recurrence of gastrointesti-
nal tract tumors compared with EMR [19]. ESD should therefore
be the preferred technique because it provides the most reliable
histopathologic assessment for accurate staging. Moreover, this
technique potentially enables the endoscopic treatment of chal-
lenging lesions, such as those that are nonlifting, measure more
than 20mm, or are suspected of deep mucosal invasion. On the
other hand, ESD is more time-consuming and associated with
more serious complications than the other techniques, so that ex-
pertise and experience are required [19,20].
This study sought to assess the efficacy, safety, and long-term re-
sults of ESD in neoplasia associated with Barrett’s esophagus in a
large number of patients referred to a tertiary center.
Patients and methods
!
Patients
Our study selected patients from a prospective registry of more
than 300 patients treated with endoscopic resection or ablation
(RFA, argon plasma coagulation [APC]) of Barrett’s neoplasia and
followed in our department between January 2007 and February
2014. Indications for ESD were as follows:
1. Barrett’s esophagus containing HGD or superficial EAC;
2. visible lesions (Paris classification 0-I/II [21]) that were multi-
ple, measured more than 15mm, were poorly lifting (no rise
after submucosal injection or no rise during suction with the
multiband mucosectomy [MBM] cap), or were suspected of
submucosal infiltration (T1sm1) at endoscopy or endoscopic
ultrasonography;
3. no sign of deeper invasion (>sm2 or T2); and
4. no sign of metastatic disease on endoscopic ultrasonography
or computed tomography.
ESD was done only when all of these criteria were met. EMR or
ablation techniques were offered to the other patients. Only
charts from patients treated with ESD were retrospectively ana-
lyzed. The following clinical variables were collected in the ESD
cohort and reviewed: patient age at the time of diagnosis of Bar-
rett esophagus and ESD procedure; patient sex; risk factors for
nonlifting lesions (previous Barrett esophagus-related endo-
scopic resection, esophageal surgery, or radiotherapy); risk fac-
tors for complications (strictures, portal hypertension, or antico-
agulation); and proton pump inhibitor (PPI) use. The study was
approved by the Faculty of Medicine’s ethics committee and in-
stitutional review board. Before each ESD procedure, written in-
formed consent was obtained.
Procedures
All ESD procedures were carried out by three experienced opera-
tors (P.H.D., H.P., and R.Y.). An anesthesiologist administered deep
sedation with a continuous intravenous propofol infusion during
all endoscopic procedures, along with tracheal intubation. Car-
bon dioxide insufflation was routinely used. We employed high
resolution video endoscopes with white light and narrow-band
imaging (GIF-H180, GIF-H190, or GIF-HQ190; Olympus Medical
Systems, Tokyo, Japan) for detailed Barrett esophagus evaluation.
Circumferential and maximum extent of Barrett esophagus were
Fig.1 En bloc and curative resection with endo-
scopic submucosal dissection in a 60-year-old pa-
tient with carcinoma-associated Barrett’s esopha-
gus. aEndoscopic view of C2 M3 Barrett’s esopha-
gus with a 2-cm lesion, Paris classification 0-IIa.
b Coagulation markings around the suspected
lateral margin of the neoplastic area with a safety
margin. c Dissection of the submucosa with a
DualKnife. d Resection area after dissection and
hemostasis.
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described according to the Prague classification [22]. The size and
type of visible defects were reported according to the Paris endo-
scopic classification [21].
The type of ESD knife used for the procedures was recorded. The
knife tip was used in soft coagulation mode to delineate the edge
of the endoscopic resection area, with a 3– to 5-mm safety mar-
gin (●" Fig.1). The mucosa was lifted by means of a submucosal
injection of 30% gelatin (Geloplasma, 500mL mixed with 1mg of
epinephrine and 1mL of methylene blue for staining; Fresenius
Kabi, Schelle, Belgium). Incision and dissection were performed
in the endocut and swift coagulation modes, respectively (Vio
300; ERBE, Diegem, Belgium). Hemostasis was achieved with ei-
ther the knife tip or a Coagrasper (Olympus Belgium, Aartselaar,
Belgium) in soft coagulation mode. Once the specimen was ex-
tracted, all residual superficial and perforating vessels were coa-
gulated. We recorded the procedure duration time, endoscopic
resection circumferential diameter, use of complementary endo-
scopic techniques (EMR, APC), and post-procedural oral corticos-
teroid therapy. ESD failure was defined as failure to achieve com-
plete resection with ESD because of strong adherence with no
safe dissection plane, uncontrollable bleeding, or perforation.
Full resection of the neoplasia and surrounding Barrett esopha-
gus was attempted in a single session if the Barrett mucosa was
not circumferential.
Adverse events
Adverse events were defined as early (<48 hours) or late (>48
hours). Procedural bleeding that could be managed endoscopi-
cally with the knife, hemostatic forceps, or hemoclips was not
considered a complication. Major procedural bleeding that was
unmanageable by endoscopic means and delayed bleeding that
required endoscopic re-evaluation or red blood cell transfusion
were considered adverse events. Perforation was defined as a
visible hole in the esophageal wall or radiologic evidence of col-
lected extramural fluid. A stricture was determined to be present
when it was difficult or impossible to pass a gastroscope through
the resection area at 2 weeks or more following ESD.
Histopathologic evaluation of resected specimens
Each specimenwas pinned downwith needles immediately after
removal and fixed in formalin for 24 hours. If en bloc resection
had not been achieved, an attempt was made to reconstruct the
topography of the specimen. Photographs were taken of the fixed
specimen and recorded. The deep and lateral resection margins
of all specimens were marked with black India ink. Specimen
number and maximum diameter were noted. Following these
steps, the specimens were cut at 2-mm intervals into strips per-
pendicular to the main axis and along themain axis near the bor-
ders in order to assess the lateral margins precisely (●" Fig.2). The
sections were serially placed into cassettes, routinely processed,
and stained with hematoxylin and eosin.
The assessment was carried out by a senior pathologist experi-
enced in EAC diagnosis (A.J.-M.). Histopathologic reports were re-
corded in accordance with the Vienna classification [23] and Ja-
panese recommendations [24]. We evaluated presence of intes-
tinal metaplasia, size, depth of invasion, and grade of differentia-
tion (G). Vertical and horizontal margin status was assessed ac-
cording to neoplasia determination: margins free of carcinoma,
high grade intraepithelial neoplasia, or low grade intraepithelial
neoplasia (R0), or margins infiltrated with neoplasia (R1). D2–40
immunohistochemistry was used to assess for lymphatic inva-
sion, and in all cases with submucosal invasion or G3 adenocarci-
noma [25].
Follow-up
Patients were hospitalized for 24 hours following ESD and under-
went a PPI regimen at triple (3×40mg) the standard dose until
themucosawas completely healed. If the esophagogram revealed
no leakage of contrast, patients were discharged on the day fol-
lowing ESD. Endoscopic follow-up was scheduled at 2 weeks for
all patients, to check for postoperative stricture and initiate a
preventive dilation program. In the event of increasing dysphagia
or lumen narrowing, repeated dilations with controlled radial ex-
pansion balloon dilators (Boston Scientific, Diegem, Belgium)
were done every week and repeated until dysphagia resolution.
When refractory strictures (more than four dilations without sig-
nificant improvement) were observed, self-expandable stent
placement was considered.
When necessary, subsequent treatments aimed at removing resi-
dual Barrett esophagus were administered during follow-up
endoscopic procedures at 6, 12, and 18 months, then yearly if re-
sidual Barrett’s mucosawas still observed. These procedures took
into account patient age, co-morbidities, and willingness to con-
tinue endoscopic treatment; they were discontinued when the
mucosa had completely healed and in the absence of significant
stricture. High resolution video endoscopy, combined with nar-
row band imaging (NBI) and chromoendoscopy with 2% acetic
Fig.2 Same patient as●" Fig.1a Macroscopic view of en bloc specimen
measuring 5.6×3.6cm shows two central brownish lesions; white lines in-
dicate axis of cut. b Histologic appearance shows an esophageal adenocar-
cinoma with limited invasion of the submucosa (black arrows) and with
free vertical and horizontal margins. Final diagnosis and staging: pT1sm1,
G1, L– , V– . mm, muscularis mucosae.
Chevaux Jean Baptiste et al. Endoscopic submucosal dissection for superficial Barrett’s neoplasia… Endoscopy 2015; 47: 103–112
Original article 105
El
ec
tr
o
n
ic
re
p
ri
n
t
fo
r
p
er
so
n
al
u
se
acid staining, was used to carefully examine the esophageal scar
and mucosa. Targeted biopsy specimens were extracted from
both the columnar epithelium areas and random areas just un-
derneath the neo-squamocolumnar junction (neo-SCJ). For pa-
tients who were followed up by their referring endoscopists, all
endoscopy and histopathologic reports were requested. Surgery
or chemoradiotherapy was considered in the event of noncura-
tive endoscopic treatment in accordance with locally established
criteria of good clinical practice. When surgery was deemed nec-
essary, all histopathologic reports were requested.
End points
The rate of curative resection of carcinoma, which was defined as
a histologically complete resection of carcinoma in ESD speci-
mens, along with horizontal and vertical margins negative for
adenocarcinoma and the absence of lymphatic (L) and venous
(V) invasion, was the primary end point.
Secondary end points were as follows:
▶ rate of en bloc resection (excision of the neoplastic lesion in a
single specimen);
▶ rate of curative resection of high grade neoplasia and carcino-
ma, defined as histologically complete excision with horizon-
tal margins free of HGD;
▶ rate of curative resection of neoplasia, defined as histologically
complete excision with horizontal margins free of any low
grade or high grade dysplasia;
▶ number of adverse events;
▶ number of sessions of additional therapy required following
the first ESD;
▶ rate of complete remission of neoplasia, defined as the absence
of high grade neoplasia or carcinoma in biopsy specimens tak-
en from the esophageal mucosa and from an area immediately
distal to the neo-SCJ at most recent follow-up; and
▶ rate of complete remission of intestinal metaplasia, defined as
the endoscopic eradication of Barrett’s esophagus associated
with absence of intestinal metaplasia in biopsy specimens
taken from the esophageal mucosa and from an area immedi-
ately distal to the neo-SCJ at the end of the eradication pro-
gram.
Statistical analysis
Quantitative variables were presented as median and interquar-
tile range (IQR). Proportions were expressed as percentages.
Results
!
Baseline characteristics
The study included 75 consecutive patients. The median age of
the patients was 68 years (IQR 61–76), and 63 patients were
male (85%) (●" Table1). A total of 22 patients had risk factors for
nonlifting lesions, such as previous endoscopic treatment (17%),
esophageal surgery (11%), and radiotherapy (1.3%). Most pa-
tients (93%) were following a PPI regimen at the time of ESD. Me-
dian time between Barrett’s esophagus diagnosis and ESD was 41
months (IQR 11–190), with a median maximum segment length
of 6cm (IQR 4–9). Themedian maximum diameter of a visible le-
sionwas 20mm (IQR 10–30), and themain lesion types encount-
ered were classified as 0-IIa (55.7%) and 0-IIc (36%) according to
the Paris endoscopic classification.
Table 1 Baseline characteristics of 75 patients undergoing endoscopic sub-
mucosal dissection (ESD) for superficial Barrett’s neoplasia.
Clinical characteristics
Patient age at ESD procedure, median (IQR), y 68 (61–76)
Sex ratio, M/F 5.25
Past medical history, n (%)
Cirrhosis 4 (5)
Previous esophageal surgery 8 (11)
Previous esophageal radiotherapy 1 (1.3)
Previous endoscopic treatment 13 (17)
PPI treatment, n (%) 70 (93)
Endoscopic characteristics
Hiatal hernia, n (%) 50 (67)
Barrett’s duration, median (IQR), mo 41 (11 –190)
Barrett’s length, median (IQR), cm
Circumferential extent 2.5 (1–6.75)
Maximum segment length 6 (4–9)
Neoplastic lesion characteristics
Visible lesions, n (%) 70 (93)
Maximum diameter, median (IQR), mm 20 (10 –30)
Paris classification (70 patients), n (%)
0-Ip 1 (1.4)
0-Is, 1 (1.4)
0-IIa, 39 (55.7)
0-IIb, 4 (5.7)
0-IIc 25 (36)
IQR, interquartile range; PPI, proton pump inhibitor.
Table 2 Procedure characteristics and adverse events in 75 patients under-
going endoscopic submucosal dissection (ESD) for superficial Barrett’s neo-
plasia.
Procedure
Procedure duration, median (IQR), min 117 (100–145)
ESD failure, n (%) 2 (2.5)
ESD device used, %
DualKnife 76
FlexKnife 19
IT Knife
Nestis
HybridKnife
11
1
4
Complementary endoscopic resection technique, n (%)
Total patients 9 (12)
EMR, 5 (7)
APC, 3 (4)
EMR+APC, 1 (1)
En bloc resection, n/n (%) 66 /73 (90)
Circumferential extent, median (IQR), % 75 (66–80)
Oral corticosteroids after procedure, n, % 13 (17)
Complications, n (%)
Early ( < 48 h)
Bleeding 2 (2.7)
Perforation, 3 (4)
Late ( > 48h)
Bleeding, 0 (0)
Perforation, 0 (0)
Strictures, 45 (60)
30-day mortality 0 (0)
IQR, interquartile range; EMR, endoscopic mucosal resection; APC, argon plasma
coagulation.
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Procedural characteristics
The median procedure time for ESD was 117 minutes (IQR 100–
145), including lesion inspection, dissection, coagulation of all
visible vessels, and perforation closure when necessary (●" Table
2). En bloc resection was achieved in 90% of ESD procedures. ESD
was not possible in 2 of the 75 patients because of a nonlifting le-
sionwith abundant sites of hemorrhage in one, who had liver cir-
rhosis, and because of a perforation, treated endoscopically, in
the other.
The majority of ESD procedures (76%) were done with the Dual-
Knife (KD-650Q; Olympus Belgium).
Complementary EMR and/or APC was used in 9 ESD procedures,
for the treatment of smaller synchronous lesions or to complete
eradication of Barrett esophagus (isolated islets of Barrett’s mu-
cosa). Following the ESD procedure, to prevent strictures 13 pa-
tients (17%) were administered an oral corticosteroid regimen
that was slowly tapered. This regimen was proposed from the
end of 2012 in patients with circumferential excision and in se-
lected patients (for example, with previous stricture or eosino-
philic esophagitis).
Histopathologic outcomes
Of the 73 patients whose ESD was successful, the histology of the
resected specimen revealed intestinal metaplasia with neoplasia
in 98.6% of cases (72/73), with associated EAC in 76.4% (55/72)
(●" Table3). The EACs were limited primarily to the mucosa
(87.2%, 48/55), with 6 revealed to have invaded the submucosal
layer to less than 500 μm (sm1). On definitive histopathologic
evaluation, 30 and 6 flat (Paris 0-II) lesions presented as with
pT1m3 and pT1sm1 adenocarcinomas, respectively,. Of the 6
pT1sm1 lesions, 3 exhibited low risk characteristics, as previously
described (G1/G2, R0, L0, V0), whereas the other 3 were lesions
with undifferentiated nests. Only 1 lesion, which was classified
as stage pT1m3 with G3 differentiation, exhibited infiltration of
the lymphatic and/or venous vessels.
The primary end point of curative resection of carcinoma was at-
tained in 85% (47/55) of patients. Failure of curative resection of
carcinoma was observed among patients with lesions classified
as having G3 differentiation (n=7) and/or positive vertical
(deep) margins (n=6). Curative resection of neoplasia was
observed in 56% (40/72) of the histopathologic specimens
(●" Fig.3).
Adverse events
No major intraprocedural bleeding occurred (●" Table2). Despite
having carried out meticulous coagulation of all visible vessels,
we observed 2 patients (2.5%) with delayed bleeding in the first
48 hours, both treated endoscopically. No red blood cell transfu-
sion was required. The bleeding occurred in patients without risk
factors such as cirrhosis, anticoagulant or antiplatelet drug in-
take, or hemopathy. Of the 3 perforations recorded (4%), 2 oc-
curred during the ESD procedures, one of which had to be dis-
continued (ESD failure), and the third was diagnosed by esopha-
gography 24 hours after the ESD procedure. All perforations were
treated endoscopically, 2 with fully covered self-expandable
stents (WallFlex; Boston Scientific, Diegem, Belgium) and the
thirdwith endoclips (EZClip; Olympus Belgium). Nomediastinitis
was observed, and the clinical evolution was favorable. We re-
corded no further related complications during hospitalization.
Esophageal strictures were the only late complications, observed
in 60% (n=45) of patients. All were treated with a median num-
ber of 4 sessions of endoscopic balloon dilation (IQR 2–6). In ad-
Table 3 Histopathological
results for endoscopic submucosal
dissection (ESD) specimens.
ESD successful resection
Patients, n 73
Maximum specimen diameter, median (IQR), mm 52.5 (43 –71)
1 (1.4)
Neoplasia findings
Intestinal metaplasia only, no neoplasia, n/n (%) 1/73 (1.4)
Patients with neoplasia, n/n (%) 72 /73 (98.6)
Low grade dysplasia (LGD), n/n (% of patients with neoplasia ) 6/72 (8.3)
High grade dysplasia (HGD), n/n (% patients with neoplasia) 11 /72 (15.3)
Esophageal adenocarcinoma (EAC), n/n (% patients with neoplasia) 55 /72 (76.4)
EAC
Total, n 55
Grade of differentiation, n/n (% of EACs)
G1 31 /55 (56.4)
G2 10 /55 (18)
G3 14 /55 (25.6)
Depth of invasion, n/n (% of EACs)
pT1 m2 18 /55 (32.7)
pT1 m3 30 /55 (54.5)
pT1 sm1 6/55 (11)
pT1 sm2 0/55 (0)
pT1 sm3 1/55 (1.8)
Lymphatic/vessel invasion, n (% of EACs) 1/55 (1.8)
Resection rates, n/n (%)
Curative resection of carcinoma 47/55 (85)
Curative resection of HGD/carcinoma 42/66 (64)
Curative resection of neoplasia (CRN) 40/72 (56)
Incomplete resection of neoplasia
At lateral margin 27/72 (38)
At deep (vertical) margin 6/55 (11)
IQR, interquartile range.
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dition, 6 stents were placed, and other techniques, such as bougie
dilation, triamcinolone injection, and radial incision, were also
used.
All complications were managed endoscopically, and no ESD-
specific death was reported.
Follow-up
The median hospitalization stay was 2 days (●" Table4), and the
median follow-up period was 20 months (IQR 8.5–37.5).
Adjuvant treatment was proposed to 10 patients, based on locally
established criteria of good clinical practice, with 7 eventually
undergoing surgery (●" Table5). Surgery wasmandatory for 5 pa-
tients because of infiltratedmargins or defined G3 differentiation
with submucosal involvement (●" Table5). The 2 patients who
had pT1sm1 EACwith low risk characteristics underwent surgery
in 2010 and 2011, respectively; definitive histology revealed nei-
ther neoplasia nor positive lymph nodes. The last 3 patients could
not undergo surgery because of their age at the time of procedure
(2 of them were 90 years old) and co-morbidities. Radiotherapy
was then performed without chemotherapy because of their per-
formance status. At the most recent follow-up, 2 of those 3 pa-
tients were still alive and exhibited no recurrence.
Overall and disease-specific mortality rates were therefore 8% (n
=6) and 2.7% (n=2), respectively. The first disease-specific death
was of a 90-year-oldwoman, one of the last 3 patients mentioned
above, who presented with undifferentiated EAC (G3, pT1m3)
and infiltrated lateral margins which could not be operated on.
Radiotherapy was unsuccessful. The second disease-specific
death was in a patient who had surgery for a poorly differenti-
ated EAC (G3, pT1sm1) also with infiltrated vertical (deep) mar-
gins. This patient died 1 year later of carcinomatosis despite sur-
gical treatment.
Additional treatment methods for residual Barrett’s esophagus
were proposed to 62% of patients (42 of 68 with endoscopic fol-
low-up), with amedian of 2 sessions (IQR 2–3). RFAwas themost
frequently used technique for eradication (50%, 21 out of 42 pa-
tients). ESD, APC, and EMR were also used in 36% (15/42), 36%
(15/42), and 29% (12/42), of the patients, respectively. There
were 3 patients who required fundoplication surgery owing to
persistent peptic esophagitis despite PPI dose escalation up to
240mg/d. At the most recent endoscopic follow-up, complete
eradication of HGD or EAC had been achieved in 54 of 59 patients
(92%). Of the 5 patients exhibiting persistent HGD or EAC at the
latest follow-up, 4 were still alive, 2 were referred for surgery,
and 2 were still undergoing RFA treatment. As for complete re-
mission of -intestinal metaplasia, 43 of 59 patients (73%) showed
endoscopic and histologic eradication of intestinal metaplasia at
the end of the eradication program, with additional treatment
used when required.
We have recorded 7 metachronous lesions, defined as high grade
intraepithelial neoplasia or carcinoma detected after 2 negative
follow-up sessions of high resolution endoscopy with systematic
biopsies (●" Table4). Of these, 4 lesions consisted of HGD, all
managed with RFA (1 still being treated). The other 3 lesions
Patients referred for endoscopic treatment for early Barrett’s neoplasia
n >300
Patients treated by endoscopic submucosal dissection (ESD)
n = 75
ESD failure n = 2
Esophageal 
adenocarcinoma (EAC)
n = 55
(2 patients with curative 
resection also had 
adjuvant treatment)
High grade dysplasia 
(HGD)
n = 11
Low grade dysplasia 
(HGD)
n = 6
Intestinal metaplasia 
n = 1
Available histopathological assessment at last follow-up: n = 59
▪Complete remission of neoplasia: n = 54/59 (92 %)
▪Complete remission of intestinal metaplasia: n = 43/59 (73 %)
Endoscopic treatment for 
residual Barrett esophagus: 
n = 42
Metachronous lesions: 
n = 7/68 (10 %)
▪ HGD: n = 4 (all treated by RFA)
▪ EAC: n = 3  (endoscopic
 treatment 1, surgery 2)
Endoscopic follow-up  n = 68
         Curative resection of carcinoma: n = 47/55 (85 %)
Curative resection of HGD/carcinoma: n = 42/66 (64 %)
           Curative resection of neoplasia: n = 40/72 (56 %)
Adjuvant treatment:   10
▪ Surgery 7
 (1 patient died after 
 1 year with 
 carcinomatosis)
▪ Radiotherapy 3
 (1 patient died despite
 radiotherapy)
Fig.3 Endoscopic submucosal dissection (ESD) in
patients with superficial Barrett’s neoplasia: study
flowchart. HGD, high grade dysplasia; RFA, radio-
frequency ablation.
Chevaux Jean Baptiste et al. Endoscopic submucosal dissection for superficial Barrett’s neoplasia… Endoscopy 2015; 47: 103–112
Original article108
El
ec
tr
o
n
ic
re
p
ri
n
t
fo
r
p
er
so
n
al
u
se
were EAC, 2 treated surgically and 1 managed endoscopically.
The decision to operate was made by referring physicians.
Discussion
!
Few data are available on ESD in Barrett’s neoplasia [26–29]. In
Western countries, the high safety and success rates of EMR are
offset by technical difficulties and the risk of ESD to the esopha-
gus [30,31]. In Asian countries, Barrett’s esophagus is an uncom-
mon condition, and adenocarcinoma is still rare [32]. For these
reasons, EMR is the gold standard in current clinical practice for
endoscopic excision in Barrett’s neoplasia. The main limitation of
EMR is the piecemeal nature of the resection that is usually re-
quired, which hampers histopathologic assessment and curative
resection based on “oncology standards,” with en bloc resection
and free margins [33]. In a recent meta-analysis and systematic
review, higher rates of en bloc and curative resection were re-
ported for ESD than for EMR, irrespective of lesion size [19, 20].
In our study, en bloc resection was achieved in 90% of patients
with successful ESD, and curative resection of carcinoma in 85%
of patients (47/55) presenting with superficial carcinoma. Cura-
tive resection of carcinoma is rarely achieved with the EMR tech-
nique because of the piecemeal nature of the resection. In a pro-
spective study of 100 patients with Barrett’s neoplasia, curative
resection of carcinoma was achieved in 33% of EMR procedures,
even though lesion diameters were less than 20mm [10]. Our re-
sults have confirmed the superiority of ESD over EMR for en bloc
and curative resection of carcinoma.
It is difficult to find an assessment of the ESD technique for Bar-
rett’s neoplasia in the scientific literature, as most available
esophageal ESD data focus on squamous cell carcinoma or esoph-
agogastric junction adenocarcinoma [26,28,34,35]. Moreover,
definitions of complete and curative resection differ slightly
among studies. ESD efficacy in this particular situation has been
evaluated in three studies: a prospective trial from Germany [27]
and one prospective [28] and one retrospective study [36] from
Japan involving 30, 25, and 23 patients, respectively. Complete
resection was achieved in 38.5%, 64%, and 85% of patients in
these studies, respectively [27,28,36]. The reason for incomplete
resection of neoplasia in patients who did not undergo surgery
was the presence of systematically infiltrated lateral margins,
which were difficult to recognize before endoscopic treatment.
These data underscore the need for more advanced imaging tech-
niques to assess Barrett’s neoplasia before and during endoscopic
treatment [37]. Furthermore, a recent study reported a subsqua-
mous extension of intestinal metaplasia in 98% of patients with
this condition [38]. The authors consequently advised that any
resection of neoplastic Barrett’s esophagus should extend for at
least 1cm into the squamous epithelium [38]. In our study, mark-
ings were usually placed 3mm outside the lesions, and the resec-
tion aimed to excise the lesion and all the markings. This may ac-
count for the higher rate of curative resection of carcinoma (85%)
observed in our patients, with larger specimens resected (medi-
an 52.5mm), although with an unfortunately higher stricture
rate owing to the greater circumferential extent of excision (me-
dian 75%).
One unexpected finding in our study was the high G3 rate, ob-
served in 25% of patients with adenocarcinomas, along with the
deep invasion rate, to more than pT1m2 in 67% (37/55) of cases.
This findingmay be due either to the case selection process (large
visible lesions and referral center for ESD) or to an improved
pathologic assessment in en bloc resections. Indeed, a piecemeal
resection of mucosal carcinoma may lead to the understaging of
deeper invasion or nests of undifferentiated cancer [39]. Even flat
(Paris 0-II) lesions were revealed to harbor carcinoma that inva-
ded the muscularis mucosae, which might not be properly asses-
sed histologically in a piecemeal fashion. In addition, 7 patients
(9%) were given a diagnosis of submucosal carcinoma. Of these,
3 exhibited low risk characteristics (R0, L0, V0, G1/G2) [5, 40], 2
of whom underwent surgery, with no residual neoplasia report-
ed on post-surgical histopathology. The third patient underwent
endoscopic surveillance, with no recurrence reported at latest
follow-up.The 4 other patients presented with high risk lesions
(G3 and/or positive vertical [deep] margin), yet post-surgical his-
topathology revealed no residual carcinoma for 2 of them. One
patient died of post-surgical complications, reminding us of the
higher mortality risk for surgical candidates.
To prevent metachronous lesions, additional eradication tech-
niques have been recommended in the context of residual Bar-
rett’s esophagus. The lower curative resection rate for dysplasia
observed in our study (64% when only HGD is considered and
56% when both low and high grade dysplasia are considered at
the horizontal margins) confirmed the frequent presence of adja-
cent intraepithelial neoplasia in the remaining Barrett’s mucosa.
Additional treatment, consisting primarily of RFA, was therefore
advised for a large proportion of our patients (65%, 44 /68), with
their age, co-morbidities, and willingness to pursue treatment
taken into account. At the end of the eradication program, com-
plete endoscopic eradication of Barrett’s esophagus with no
intestinal metaplasia was achieved in 73% of patients (43/59).
Table 4 Clinical, endoscopic, and histologic follow-up of patients who un-
derwent endoscopic submucosal dissection (ESD) for superficial Barrett’s
neoplasia.
Clinical course
Patients, n 75
Hospitalization duration, median (IQR), d 2 (2–2)
Follow-up duration, median (IQR), mo 20 (8.5–37.5)
Endoscopic follow-up, n (%) 68 (91)
Surgery, n (%) 9 (12)
Radiotherapy, n (%) 3 (4)
Overall mortality, n (%) 6 (8)
Disease-specific mortality, n (%) 2 (2.7)
Endoscopic follow-up
Patients, n 68
Residual Barrett’s esophagus
Patients treated for residual Barrett’s, n/n (%) 42 /68 (62)
Sessions for eradication of residual Barrett’s, median
(IQR), n
2 (2–3)
Endoscopic technique used, n/n (%)
EMR 12/42 (29)
ESD 15/42 (36)
APC 15/42 (36)
RFA 21/42 (50)
Metachronous lesions, n (%) 7/68 (10)
HGD 4
Esophageal adenocarcinoma (EAC) 3
Histopathologic follow-up
Patients, n 59
Complete remission of neoplasia, n/n (%) 54/59 (92)
Complete remission of intestinal metaplasia, n/n (%) 43/59 (73)
IQR, interquartile range; EMR, endoscopic mucosal resection; APC, argon plasma
coagulation; RFA, radiofrequency ablation; HGD, high grade dysplasia.
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These results were similar to those published in the recent scien-
tific literature, especially in light of the long-segment Barrett’s
esophagus treated in our cases (median maximum segment
length 6cm, IQR 4–9). In ameta-analysis that assessed the effica-
cy of RFA in Barrett’s esophagus eradication, complete eradica-
tion of intestinal metaplasia was achieved in 78% of patients (95
%CI 70%–86%) [41]. In a systematic review of 22 studies aimed at
comparing the RFA and EMR techniques, the success of eradica-
tion of intestinal metaplasia was variable across studies, ranging
from 55% to 100% following RFA, and from 80% to 96% following
complete EMR [42].
During follow-up, 7 metachronous neoplastic lesions (HGD/EAC)
appeared. In a retrospective study by Pech et al. involving 279 pa-
tients with EMR, metachronous lesions were found in 74 patients
(26.5%) during follow-up [9]. Piecemeal resection was the main
risk factor associated with recurrence [9]. Other risk factors con-
sisted of long-segment Barrett’s esophagus, time until complete
local remission longer than 10 months, multifocal neoplasia,
and no ablative therapy of Barrett’s esophagus following com-
plete local excision [9]. The risk for recurrent lesions in the diges-
tive tract was significantly higher with EMR than with ESD in a
recent meta-analysis and systematic review [19,20]. This has
been confirmed by our results, with metachronous lesions re-
ported in 9% of patients, all treatable endoscopically or by sur-
gery. However, no conclusion in terms of metachronous lesion
occurrence could be drawn from our results compared with
those of Pech et al. because their follow-up was longer (63
months), and EMR was not the only endoscopic treatment for
the resection of Barrett’s neoplasia [9].
In our study, 5 early complications occurred (6.7%, among 75 pa-
tients), which were all managed endoscopically. In the German
and Japanese studies, the rate of early complications varied be-
tween 6.6% and 4% [27,28]. These rates were similar to those
previously described with the EMR technique [9,10,43]. This re-
lative safety was offset by the rate of esophageal strictures, occur-
ring in more than half of patients, which is higher than rates pre-
viously described with EMR (0%–25%), and strictures can ham-
per quality of life [10,44]. However, in the SRER approach, stric-
tures were also observed in more than 50% of patients [17,45].
Ono et al. analyzed predictors of postoperative stricture follow-
ing 11 ESD procedures for superficial squamous cell carcinoma
[46]. In a multivariate analysis, circumferential extent involving
more than 75% of the whole lumen and invasion depth to greater
than pT1m2 were significantly associated with stricture occur-
rence [46]. Tumor size (>59% of the circumference) was also
thought potentially to be involved [47]. In our study, the median
circumferential extent of resection was 75%, and invasion depth
was to greater than pT1m2 in more than 60% of patients, two fac-
tors that may explain the high stricture rate observed in our pa-
tients. In addition, approximately one-third of patients had un-
dergone previous esophageal surgery, radiotherapy, or endo-
scopic treatment, whichmight have facilitated fibrosis formation.
Oral or topical corticosteroids can reduce the need for dilation
and prevent stricture occurrence, as shown in recent studies
Table 5 Adjuvant surgery or chemotherapy in 10 patients following endoscopic submucosal dissection (ESD) for superficial Barrett’s neoplasia: treatment and
subsequent histopathology results.
Patient
no.
Age, y, sex Specimen
size, mm
Histopathology findings Adjuvant treatment
Histopathologic evaluation/
Outcomes
Lesion classification Lateral
margin
Deep (vertical)
margin
1 66, M 44 EAC
pT1sm3, G2, L0, V0
R0 R1 Abdominothoracic esophageal resection
Intestinal metaplasia + , HGD+ , N0
No recurrence at last follow-up
2 72, M 35 EAC
pT1 sm1, G3, L0, V0
R0 R1 Abdominothoracic esophageal resection
pT1m3, intestinal metaplasia + , HGD+ , N0
Post-surgery death
3 70, M 56 EAC
pT1sm1, G1, L0, V0
R0 R0 Abdominothoracic esophageal resection
Intestinal metaplasia + , N0
No recurrence at last follow-up
4 59, M 38 EAC
pT1sm1, G2, L0, V0
R0 R0 Abdominothoracic esophageal resection
No tumor, N0
No recurrence at last follow-up
5 68, M 57 EAC
pT1sm1, G3, L0, V0
R0 R1 Abdominothoracic esophageal resection
pT1sm1, G3, intestinal metaplasia + , LGD+ ,
HGD+ , N1
Carcinomatosis and death 1 year later
6 67,, M 65 EAC
pT1sm1, G3, L0, V0
R0 R1 Abdominothoracic esophageal resection
HGD+ , N0
No recurrence at last follow-up
7 54, M 65 EAC
pT1m3, G3, L0, V0
R0 R1 Abdominothoracic esophageal resection
Intestinal metaplasia + , N0
No recurrence at last follow-up
8 90, F 40 EAC
pT1m3, G3, L0, V0
R0 R1 Inoperable patient, radiotherapy
Carcinomatosis and death 1 year later
9 90, M 32 EAC
pT1m3, G3, L0, V0
R1 R0 Inoperable patient, radiotherapy
No recurrence at last follow-up
10 75, M 45 EAC
pT1m3, G3, L + , V0
R0 R0 Inoperable patient, radiotherapy
No recurrence at last follow-up
M, male; F, female; EAC, esophageal adenocarcinoma; L, lymphatic invasion; N, lymph node; V, venous invasion; HGD, high grade dysplasia; LGD, low grade dysplasia;+ , present
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[46,48]. Although some of our patients are now receiving treat-
ment with oral corticosteroids, their clinical benefit is still under
investigation.
The median procedure duration was 117 minutes, which is long-
er than that reported with EMR and in previous ESD studies [27,
28]. Performing ESD in the Barrett’s mucosa or near the esopha-
gogastric junction can prove difficult owing to fibrosis, possible
hiatal hernia, or previous treatment [49]. A recent report from Ja-
pan reported a median procedure duration of 95 minutes (range
30–210 minutes) for lesions with a median tumor size of 15mm
(range 5–60mm) [36]. The difference seen in our study might be
accounted for by our larger specimen sizes (52.5mm, IQR 43–71)
and the fact that our procedure duration included not only the
dissection but also all the other ESD steps, namely, inspection,
marking, incision, dissection, meticulous coagulation, and per-
foration closure when necessary.
The main limitations of this study were its retrospective and un-
controlled design, as it was conducted in a single tertiary center
with comprehensive experience in ESD and Barrett’s neoplasia.
Our reported safety and efficacy rates may therefore differ from
those of centers where ESD is practiced less frequently. Besides,
because of its retrospective and uncontrolled design, the study
may suffer from selection and inclusion bias.
In summary, this is the largest series of ESD for Barrett-associated
superficial neoplasia. ESD appears to be safe and effective in an
experienced center, with a high rate of curative resection of car-
cinoma. Based on our results, ESD should be considered in select-
ed patients, such those with lesions larger than 15mm, poorly
lifting tumors, or lesions at risk for submucosal invasion. Indeed,
an en bloc resection may provide a better histologic evaluation of
some lesions, such as thosewith deeper invasion (>pT1m2) or G3
differentiation, as they were more frequently observed in our pa-
tients than in patients in previous EMR trials. Because ESD has
not been shown to be superior to EMR for the excision of mucosal
cancer, multicenter randomized controlled trials are needed to
define the role of ESD compared with EMR. The high rate of
esophageal stenosis is a major drawback of extensive endoscopic
resection, including ESD, and techniques to prevent post-ESD
strictures should be investigated further.
Competing interests: None
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